Show simple item record

Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2

dc.rights.licenseopenen_US
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCLAIRON, Quentin
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPRAGUE, Mélanie
dc.contributor.authorPLANAS, Delphine
dc.contributor.authorBRUEL, Timothée
dc.contributor.authorHOCQUELOUX, Laurent
dc.contributor.authorPRAZUCK, Thierry
dc.contributor.authorSCHWARTZ, Olivier
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorGUEDJ, Jérémie
dc.date.accessioned2024-09-13T12:34:36Z
dc.date.available2024-09-13T12:34:36Z
dc.date.issued2023-08-01
dc.identifier.issn1553-734Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201580
dc.description.abstractEnBecause SARS-CoV-2 constantly mutates to escape from the immune response, there is a reduction of neutralizing capacity of antibodies initially targeting the historical strain against emerging Variants of Concern (VoC)s. That is why the measure of the protection conferred by vaccination cannot solely rely on the antibody levels, but also requires to measure their neutralization capacity. Here we used a mathematical model to follow the humoral response in 26 individuals that received up to three vaccination doses of Bnt162b2 vaccine, and for whom both anti-S IgG and neutralization capacity was measured longitudinally against all main VoCs. Our model could identify two independent mechanisms that led to a marked increase in measured humoral response over the successive vaccination doses. In addition to the already known increase in IgG levels after each dose, we identified that the neutralization capacity was significantly increased after the third vaccine administration against all VoCs, despite large inter-individual variability. Consequently, the model projects that the mean duration of detectable neutralizing capacity against non-Omicron VoC is between 348 days (Beta variant, 95% Prediction Intervals PI [307; 389]) and 587 days (Alpha variant, 95% PI [537; 636]). Despite the low neutralization levels after three doses, the mean duration of detectable neutralizing capacity against Omicron variants varies between 173 days (BA.5 variant, 95% PI [142; 200]) and 256 days (BA.1 variant, 95% PI [227; 286]). Our model shows the benefit of incorporating the neutralization capacity in the follow-up of patients to better inform on their level of protection against the different SARS-CoV-2 variants. Trial registration : This clinical trial is registered with ClinicalTrials.gov, Trial IDs NCT04750720 and NCT05315583.
dc.description.sponsorshipInitiative for the creation of a Vaccine Research Instituteen_US
dc.description.sponsorshipIntegrative Biology of Emerging Infectious Diseases - ANR-10-LABX-0062en_US
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enModeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
dc.title.alternativePLoS Comput Biolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pcbi.1011282en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37549192en_US
bordeaux.journalPLoS Computational Biologyen_US
bordeaux.pagee1011282en_US
bordeaux.volume19en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut Pasteuren_US
bordeaux.identifier.funderIDFondation pour la Recherche Médicaleen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
bordeaux.identifier.funderIDSanofien_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20Computational%20Biology&rft.date=2023-08-01&rft.volume=19&rft.issue=8&rft.spage=e1011282&rft.epage=e1011282&rft.eissn=1553-734X&rft.issn=1553-734X&rft.au=CLAIRON,%20Quentin&PRAGUE,%20M%C3%A9lanie&PLANAS,%20Delphine&BRUEL,%20Timoth%C3%A9e&HOCQUELOUX,%20Laurent&rft.genre=article


Files in this item

Thumbnail
Name:
BPH_PLoSComputBiol_2023_Clairon.pdf
Size:
3.879Mb
Format:
PDF
View/Open
No Thumbnail [100%x80]
Name:
license_rdf
Size:
914bytes
Format:
application/rdf+xml
View/Open

This item appears in the following Collection(s)

Show simple item record